The rise in antibiotic resistance is a global health concern that necessitates judicious use of these drugs. This article aims to provide a comprehensive guide to promote rational use of antibiotics in clinical practice.
Antibiotic resistance occurs when bacteria mutate in response to the use of these drugs. It is a natural phenomenon that is accelerated by the misuse and overuse of antibiotics. The consequences of antibiotic resistance are severe, leading to longer hospital stays, higher medical costs, and increased mortality.
Rational antibiotic use involves prescribing the right drug, at the right dose, for the right duration, and at the right time. It is important to make use of diagnostic tests to identify the causative organism and its antibiotic susceptibility. Empirical therapy should be tailored based on local epidemiological data and individual patient factors. Antibiotics should be de-escalated whenever possible, based on culture results.
Antimicrobial stewardship programs (ASPs) are coordinated interventions designed to improve and measure the appropriate use of antimicrobials. They involve a multidisciplinary team that includes infectious disease physicians, pharmacists, microbiologists, and infection control professionals. ASPs have been shown to reduce antibiotic resistance, improve patient outcomes, and decrease healthcare costs.
Education of healthcare professionals and patients is a key component of rational antibiotic use. Healthcare professionals need to be updated about the latest guidelines and resistance patterns. Patients need to be counseled about the importance of adherence to prescribed therapy, the risks of self-medication, and the appropriate use of antibiotics.
Rational use of antibiotics is a collective responsibility that involves healthcare professionals, patients, and policy makers. By adhering to the principles of rational antibiotic use and implementing antimicrobial stewardship programs, we can curb the rise of antibiotic resistance and ensure the longevity of these life-saving drugs.
1.
Quizartinib Benefit in AML Limited to FLT3-Mutated Subgroup
2.
Olaparib-Abiraterone in mCRPCs Selected by Biomarkers Outperforms Each Agent by Itself.
3.
Top 10 questions about breast cancer answered
4.
Brigatinib Makes Its Case for ALK-Positive ALCL in Small Study
5.
For some patients with bladder cancer that has invaded the muscle, trimodality therapy is just as effective as radical cystectomy.
1.
Single-Cell Lineage Tracing in Hematology: Decoding the Cellular Blueprint of Blood Disorders
2.
Unlocking the Potential of Red Bone Marrow in the Formation of Blood Cells
3.
Cancer Vaccines in Solid Tumors: Current Landscape, Mechanisms, and Clinical Implications
4.
Neoepitope Vaccines in Oncology: Precision, Sequencing, and Immunotherapy Frontiers
5.
Intratumoral Drug Distribution as a Determinant of Therapeutic Success
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part VII
2.
Evolving Space of First-Line Treatment for Urothelial Carcinoma- Case Discussion
3.
Treatment Sequencing Strategies in ALK + NSCLC Patients with CNS Diseases
4.
Efficient Management of First line ALK-rearranged NSCLC
5.
Current Scenario of Blood Cancer- Further Discussion on Genomic Testing & Advancement in Diagnosis and Treatment
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation